Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment

Izawa, Kumi; Maehara, Akie; Isobe, Masamichi; Yasuda, Yuka; Urai, Makoto; Hoshino, Yasutaka; Ueno, Keigo; Matsukawa, Toshihiro; Takahashi, Mariko; Kaitani, Ayako; Shiba, Emiko; Takamori, Ayako; Uchida, Shino; Uchida, Koichiro; Maeda, Keiko; Nakano, Nobuhiro; Yamanishi, Yoshinori; Oki, Toshihiko; Voehringer, David; Roers, Axel; Nakae, Susumu; Ishikawa, Junko; Kinjo, Yuki; Shimizu, Toshiaki; Ogawa, Hideoki; Okumura, Ko; Kitamura, Toshio; Kitaura, Jiro

doi:10.1038/s41598-017-04647-z

Download PDF

Article
Open access
Published: 27 June 2017

Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment

Kumi Izawa^1,2,
Akie Maehara^1,2,
Masamichi Isobe^1,2,
Yuka Yasuda³,
Makoto Urai⁴,
Yasutaka Hoshino⁴,
Keigo Ueno⁴,
Toshihiro Matsukawa^2,5,
Mariko Takahashi²,
Ayako Kaitani^1,2,
Emiko Shiba^1,6,
Ayako Takamori¹,
Shino Uchida^1,7,
Koichiro Uchida¹,
Keiko Maeda¹,
Nobuhiro Nakano¹,
Yoshinori Yamanishi^2,8,
Toshihiko Oki²,
David Voehringer⁹,
Axel Roers¹⁰,
Susumu Nakae¹¹,
Junko Ishikawa³,
Yuki Kinjo⁴,
Toshiaki Shimizu^1,6,
Hideoki Ogawa¹,
Ko Okumura¹,
Toshio Kitamura² &
…
Jiro Kitaura^1,2

Scientific Reports volume 7, Article number: 4298 (2017) Cite this article

2065 Accesses
23 Citations
Metrics details

Subjects

Abstract

Sepsis is a serious clinical problem. Negative regulation of innate immunity is associated with sepsis progression, but the underlying mechanisms remains unclear. Here we show that the receptor CD300f promotes disease progression in sepsis. CD300f ^−/− mice were protected from death after cecal ligation and puncture (CLP), a murine model of septic peritonitis. CD300f was highly expressed in mast cells and recruited neutrophils in the peritoneal cavity. Analysis of mice (e.g., mast cell-deficient mice) receiving transplants of wild-type or CD300f ^−/− mast cells or neutrophils indicated that CD300f deficiency did not influence intrinsic migratory abilities of neutrophils, but enhanced neutrophil chemoattractant production (from mast cells and neutrophils) in the peritoneal cavity of CLP-operated mice, leading to robust accumulation of neutrophils which efficiently eliminated Escherichia coli. Ceramide-CD300f interaction suppressed the release of neutrophil chemoattractants from Escherichia coli-stimulated mast cells and neutrophils. Administration of the reagents that disrupted the ceramide-CD300f interaction prevented CLP-induced sepsis by stimulating neutrophil recruitment, whereas that of ceramide-containing vesicles aggravated sepsis. Extracellular concentrations of ceramides increased in the peritoneal cavity after CLP, suggesting a possible role of extracellular ceramides, CD300f ligands, in the negative-feedback suppression of innate immune responses. Thus, CD300f is an attractive target for the treatment of sepsis.

Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis

Article Open access 19 June 2023

CD200Rhigh neutrophils with dysfunctional autophagy establish systemic immunosuppression by increasing regulatory T cells

Article 05 February 2024

TNF-α-induced protein 8-like 2 negatively regulates the immune function of dendritic cells by suppressing autophagy via the TAK1/JNK pathway in septic mice

Article Open access 30 October 2021

Introduction

Septic peritonitis is a life-threatening emergency. Most clinical trials of anti-inflammatory agents in septic patients have been unsuccessful. Sepsis is characterized by systemic dysregulated inflammatory responses to infection. Despite extensive studies aimed at controlling or preventing it, sepsis remains a substantial clinical problem with poor prognosis and limited therapeutic options^{1, 2}. The innate immune system is the first line of defense against bacterial infection. Tissue-resident myeloid cells―including mast cells and macrophages―detect invading bacteria or their products via pattern recognition receptors. To recruit neutrophils to infection sites, these myeloid cells release a variety of chemical mediators: neutrophil chemoattractants (e.g., leukotriene B4 [LTB4], macrophage inflammatory protein 2 [MIP2], and keratinocyte-derived chemokine [KC]) and vascular inflammation- and permeability-inducing factors (e.g., leukotrienes [LTs] and histamine). In turn, the recruited neutrophils themselves release neutrophil chemoattractants to further recruit neutrophils, which engulf and kill bacteria, thereby preventing the bacteria from spreading^3,4,5,6. Nonetheless, once bacterial infections overcome such coordinated innate responses, sepsis progresses with systemic hyper-inflammation followed by immunosuppression. Most clinical trials of anti-inflammatory agents in septic patients have been unsuccessful². Excessive activation of innate immunity is counterbalanced by negative signaling cascades^{7, 8}. Therefore, understanding the inhibitory mechanisms in innate host responses is necessary to develop effective treatments of sepsis. Cecal ligation and puncture (CLP) is the standard model of septic peritonitis triggered by self-infection with intestinal bacteria such as Escherichia coli (E. coli). A variety of immune cells and receptors regulate CLP-induced sepsis during its different phases^9,10,11. Here, we delineate the critical role of mast cell- and neutrophil-expressed CD300f (also called leukocyte mono-immunoglobulin-like receptor 3 [LMIR3] or CMRF-35-like molecule-1 [CLM-1])^12,13,14,15 in innate host responses.

CD300f belongs to the paired activating and inhibitory receptor family CD300 (also called LMIR, CLM, or myeloid-associated Ig-like receptor [MAIR])^{12,13,14,15,16,17,18}. The inhibitory receptor CD300f harbors two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a single immunoreceptor tyrosine-based switch motif (ITSM) in the cytoplasmic region, and CD300f is expressed in myeloid cells, including mast cells and neutrophils^12,13,14,15. Recent studies point to specific lipids or lipid-binding proteins as ligands of CD300^{13, 19,20,21,22,23,24,25,26}. We recently identified extracellular ceramide as a ligand of CD300f¹³. Ceramides are composed of a long-chain or sphingoid base linked to a fattty acid via an amide bond. Ceramides play an important role not only as structural elements but also as regulators of a variety of cellular processes including differentiation, inflammation, proliferation, and apoptosis²⁷. Ceramide-CD300f interaction inhibits IgE-dependent allergic responses¹³, ATP-mediated experimental colitis²⁸, or lipopolysaccharide (LPS)-induced skin inflammation²⁹. However, the roles of ceramide-CD300f interaction in sepsis, including septic peritonitis, have remained elusive.

In the present study, we demonstrate that in a model of septic peritonitis, disrupting the ceramide-CD300f interaction remarkably stimulates neutrophil recruitment to sites of infection and protects mice from septic death.

Results

CD300f ^−/− mice were highly resistant to CLP-induced sepsis

To clarify the role of CD300f in innate host responses, we used CLP, a model of septic peritonitis, in WT and CD300f ^−/− mice. CD300f ^−/− mice showed prolonged survival after CLP or mild CLP as compared with WT mice (Fig. 1a,b). Likewise, CD300f ^−/− mice were less prone to septic death after intraperitoneal inoculation with a minimal lethal dose of E. coli (Fig. 1c). Notably, lower counts of E. coli as well as remarkably lower levels of the proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6 were found in both peritoneal lavage fluid (PLF) and peripheral blood (PB) collected 24 h after CLP in CD300f ^−/− mice compared with WT mice (Fig. 1d,e). Thus, the vascular spread of E. coli and the concomitant hyper-inflammatory responses were prevented in CD300f ^−/− mice as early as 24 h after CLP, indicating that CD300f ^−/− mice were highly resistant to CLP-induced sepsis.

Markedly enhanced accumulation of neutrophils was observed in the peritoneal cavity of CD300f ^−/− mice after CLP

We then performed histological analysis of cecum sections, which showed no significant differences between WT and CD300f ^−/− mice after a sham operation (Fig. 2a). WT mice, but not CD300f ^−/− mice, showed severe destruction or a complete loss of mucosal architecture in cecum sections collected 4 or 24 h after CLP, respectively (Fig. 2a). Cecum sections of CD300f ^−/− mice revealed prominent submucosal edema and serosal neutrophil infiltration 4 h after CLP, and showed attenuated edema and enhanced neutrophil accumulation after 24 h (Fig. 2a). In line with the histological findings, we observed a marked increase in the number of CD11b⁺Gr-1^high neutrophils in PLF of CD300f ^−/− mice 4 h after CLP (Fig. 2b). We then measured the levels of MIP2, KC, LTB4, or cysteinyl LTs in PLF of the CLP-operated mice. The results showed higher concentrations of these chemical mediators in PLF of CD300f ^−/− mice as compared with PLF of WT mice as early as 2 h after CLP (Fig. 2c). These results led us to hypothesize that the high levels of neutrophil chemoattractants and vascular inflammation- and permeability-inducing factors recruit substantial numbers of neutrophils to the peritoneal cavity of CD300f ^−/− mice.

Ceramide-CD300f interaction suppressed the release of neutrophil chemoattractants from mast cells and neutrophils in response to the presence of E. coli

To clarify the role of the interaction between CD300f and its ligand ceramide in CLP, we examined the levels of extracellular ceramide species in PLF or plasma from WT mice³⁰. The results revealed that several kinds of ceramide (N-palmitoyl-D-erythro-sphingosine [d18:1/16:0], N-stearoyl-D-erythro-sphingosine [d18:1/18:0], N-arachidoyl-D-erythro-sphingosine [d18:1/20:0], N-behenoyl-D-erythro-sphingosine [d18:1/22:0], N-lignoceroyl-D-erythro-sphingosine [d18:1/24:0], and N-nervonoyl-D-erythro-sphingosine [d18:1/24:1]) were present in PLF; the levels of ceramide species in PLF, but not in plasma, increased after CLP, implying a possible role of the ceramide-CD300f binding in this phenomena (Fig. 3a and Supplementary Fig. S1). Next, to identify the cell populations responsible for the enhanced neutrophil accumulation in CLP-operated CD300f ^−/− mice, we examined CD300f expression in peritoneal myeloid cells of WT mice. Notably, CD300f was highly expressed in resident mast cells and in the recruited neutrophils, whereas it was barely expressed in peritoneal macrophages (Fig. 3b). We then tested whether the binding of ceramide to CD300f inhibits the release of neutrophil chemoattractants from these myeloid cells in response to the presence of E. coli. To this end, bone marrow-derived mast cells (BMMCs) were stimulated with E. coli on plates coated with ceramide or phosphatidylcholine (PC) as a control. The CD300f deficiency failed to alter the release of the indicated chemical mediators from the stimulated BMMCs in the absence of ceramide (Fig. 3c–e). On the other hand, the ceramide-CD300f interaction specifically inhibited the release of MIP2, KC, LTB4, LTC4, or β-hexosaminidase (a marker of degranulation) from WT BMMCs, but not from CD300f ^−/− BMMCs, in response to the presence of E. coli (Fig. 3c–e). Similar experiments with BMMC transfectants confirmed that the disruption of ITIMs and ITSM of CD300f attenuated the inhibition of E. coli-stimulated mast cell activation by the ceramide-CD300f binding (Supplementary Fig. S2a–c)¹³. Thus, the ceramide-CD300f interaction suppressed E. coli-stimulated mast cell activation via ITIMs and ITSM of CD300f. Similarly, the ceramide-CD300f interaction also suppressed the release of neutrophil chemoattractants from neutrophils stimulated by E. coli (Fig. 3f and Supplementary Fig. S3). In contrast, the release of these neutrophil chemoattractants was not inhibited by the ceramide-CD300f interaction in peritoneal macrophages, presumably due to the low levels of CD300f expression (Fig. 3g). On the other hand, neither LMIR3 expression nor the ceramide-CD300f interaction significantly influenced the bactericidal activity of neutrophils or BMMCs against E. coli (Supplementary Fig. S4a,b); this finding is suggestive of a limited role of the ceramide-CD300f binding in innate immune responses.

CD300f ^−/− neutrophils recruited to the peritoneal cavity contributed to enhanced neutrophil accumulation in the CLP model

To clarify the in vivo role of CD300f-deficient neutrophils in promoting neutrophil accumulation in our CLP model, we intraperitoneally injected equal numbers of WT or CD300f ^−/− neutrophils (Ly5.2⁺) into CLP-operated WT mice (Ly5.1⁺). Transfusion of 10⁷ neutrophils, irrespective of the expression of CD300f, equally improved survival of the CLP-operated mice (Supplementary Fig. S5), suggesting that an adequate number of recruited neutrophils can prevent CLP-induced sepsis. On the other hand, transfusion of 10⁶ CD300f ^−/− neutrophils, but not of WT neutrophils, increased survival and the number of Ly5.1⁺ neutrophils recruited to (and the levels of MIP2, KC, and LTB4 in) the peritoneal cavity of the CLP-operated WT mice (Fig. 4a–c). We then determined whether the CD300f deficiency enhances the intrinsic migratory ability of neutrophils themselves. Transwell migration assays revealed that PLF of CLP-operated CD300f ^−/− mice attracted more neutrophils than did PLF of CLP-operated WT mice, and that equivalent numbers of WT or CD300f ^−/− neutrophils migrated into the same PLF (Fig. 4d). After that, to next compare the migratory ability between WT and CD300f ^−/− neutrophils in vivo, CFSE-labeled CD300f ^−/− neutrophils mixed in the ratio of 1:4, 1:1, or 4:1 with WT neutrophils were intravenously injected into WT mice 1 h before CLP. The proportions of CD300f ^−/− cells among CFSE-positive peritoneal neutrophils were also similar to their proportions among the CFSE-positive PB neutrophils (Fig. 4e). These data indicated that neutrophil chemoattractants released by CD300f ^−/− neutrophils rather than the intrinsic migratory ability of CD300f ^−/− neutrophils contributed to the enhanced accumulation of neutrophils in CLP-operated CD300f ^−/− mice.

CD300f ^−/− mast cells played an important role in the enhanced neutrophil accumulation in the CLP model

To clarify the functions of CD300f ^−/− mast cells in the defense against sepsis, we used CLP in mast cell-deficient (Kit ^W-sh/W-sh) mice reconstituted intraperitoneally with WT or CD300f ^−/− BMMCs, with the two types of mice having equivalent numbers of peritoneal mast cells (Supplementary Fig. S6a,b). The reconstitution with CD300f ^−/− BMMCs, but not with WT BMMCs, improved the survival of CLP-operated Kit ^W-sh/W-sh mice (Fig. 5a), implicating CD300f ^−/− mast cells in the prolonged survival of the CLP-operated CD300f ^−/− mice. In addition, CD300f ^−/− BMMC-reconstituted Kit ^W-sh/W-sh mice were found to have greater numbers of neutrophils as well as higher levels of MIP2, KC, LTB4, and cysteinyl LTs in PLF than did WT BMMC-reconstituted Kit ^W-sh/W-sh mice (Fig. 5b,c). Similarly, a transplant of CD300f ^−/− BMMCs, but not WT BMMCs, enhanced neutrophil accumulation and improved survival after CLP in a cross of Mcpt5-Cre mice with the R-DTA mice (Mcpt5-Cre/R-DTA mice); these mice were genetically engineered to be mast cell-deficient (Fig. 5d,e and Supplementary Fig. S7)³¹. Moreover, we compared disease progression between Kit ^W-sh/W-sh mice and Kit ^W-sh/W-sh CD300f ^−/− mice. The latter mice showed slightly increased survival after CLP as compared with the former (Fig. 5f), indicating that CD300f ^−/− myeloid cells other than mast cells, possibly neutrophils, contributed to the resistance of CD300f ^−/− mice to CLP lethality. Moreover, reconstitution with CD300f ^−/− BMMCs, but not with their WT counterparts, increased the number of neutrophils in the peritoneal cavity and improved survival in CLP-operated CD300f ^−/− Kit ^W-sh/W-sh mice (Supplementary Fig. S8a–c). On the other hand, a transplant of BM-derived macrophages, irrespective of CD300f expression, equally improved survival after CLP in WT mice with macrophage/monocyte depletion by clodronate liposomes (Supplementary Fig. S9), confirming that monocytes/macrophages play a role in the resistance to CLP-induced sepsis; however, CD300f deficiency in monocytes/macrophages does not significantly influence that.

Treatment with an anti-ceramide Ab or CD300f-Fc ameliorated septic mortality after CLP

We then intraperitoneally injected CD300f-Fc or a control Fc into mice immediately after CLP and monitored survival. The CD300f-Fc-treated mice survived remarkably longer after CLP, as compared with control mice (Fig. 6a). Similarly, intraperitoneal injection of an anti-ceramide Ab, but not of a control Ab, into WT mice immediately after CLP effectively prevented septic deaths (Fig. 6b). WT mice given an injection of the anti-ceramide Ab at 1 or 3 h after CLP showed survival rates that were similar to those of the mice treated with the anti-ceramide Ab immediately after CLP (Fig. 6c). In addition, even when WT mice received an intraperitoneal injection of the anti-ceramide Ab at 7 h after CLP, this treatment was still effective against septic deaths (Fig. 6c). Accordingly, treatment with the anti-ceramide Ab, but not with a control Ab, increased the numbers of neutrophils recruited to the peritoneal cavity of WT mice 2 h after CLP; these numbers were comparable to those found in the case of CLP-operated CD300f ^−/− mice (Fig. 6d). In addition, treatment with the anti-ceramide Ab, but not with a control Ab, elevated the levels of MIP-2, KC, LTB4, and cysteinyl LTs in PLF of WT mice 2 h after CLP (Fig. 6e,f). In contrast, the same treatment failed to influence neutrophil recruitment or chemical-mediator production in CLP-operated CD300f ^−/− mice (Fig. 6d–f). In contrast, treatment with vesicle containing ceramide, but not PC or phosphatidylserine (PS), decreased the survival of WT mice after mild CLP (Fig. 6g). In line with this finding, only treatment with ceramide-containing vesicle decreased the number of neutrophils recruited to the peritoneal cavity of WT mice, but not of CD300f ^−/− mice (Fig. 6h). Thus, increasing the concentration of extracellular ceramides aggravated experimental sepsis by reducing neutrophil recruitment to the local sites of infection, whereas disruption of the ceramide-CD300f interaction prevented sepsis by stimulating neutrophil recruitment.

Discussion

A striking feature of CD300f ^−/− mice subjected to CLP is the dramatically enhanced accumulation of neutrophils after elevated production of neutrophil chemoattractants (e.g., MIP2, KC, and LTB4) and vascular permeability- and inflammation-inducing factors (e.g., cysteinyl LTs) in the peritoneal cavity, where feces-derived bacteria (e.g., E. coli) evoked inflammation. Given that CD300f deficiency enhances LPS-induced skin inflammation characterized by edema formation and neutrophil accumulation²⁹, it is possible that E. coli-derived LPS plays a certain role in the underlying pathogenesis. Notably, peritoneal exudates from CLP-operated CD300f ^−/− mice attracted more neutrophils, irrespective of CD300f expression, than did those from WT counterparts in an in vitro migration assay. In addition, WT and CD300f-deficient neutrophils had equivalent abilities to migrate from the circulating blood to the peritoneal cavity in our CLP model. Therefore, it was reasonable to assume that the enhanced neutrophil accumulation in CD300f ^−/− mice was primarily due to elevated local production of factors inducing neutrophil migration at an early time-point after CLP; peritoneal CD300f ^−/− myeloid cells should contribute to this phenomenon. On the other hand, flow cytometric analysis revealed high levels of CD300f expression in peritoneal mast cells and in recruited neutrophils, but not in peritoneal macrophages. Consistent with this, the binding of plate-coated ceramide to CD300f inhibited the release of factors (inducing neutrophil migration) from mast cells and neutrophils, but not from peritoneal macrophages, in response to the presence of E. coli. Accordingly, we hypothesized that the ceramide-CD300f binding in resident mast cells and recruited neutrophils would suppress the local production of factors inducing neutrophil migration in the CLP model. Indeed, we confirmed that ceramide species were present in PLF. Moreover, CLP substantially increased the amounts of peritoneal ceramide species; this finding is suggestive of a possible role of extracellular ceramides in the negative-feedback suppression of innate immune responses³². Expression patterns of ceramide species were different between plasma and PLF, implying that extracellular ceramides may be derived from damaged, necrotic, or apoptotic cells, but not from extravasated blood, in the peritoneal cavity after CLP. Moreover, treatment with CD300f-Fc or the anti-ceramide Ab, which disrupt the ceramide-CD300f interaction in vivo ¹³, increased the number of neutrophils recruited to and the levels of neutrophil chemoattractants in the peritoneal cavity of WT mice. In contrast, treatment with ceramide-containing vesicle, which locally upregulated ligands for CD300f¹³, decreased neutrophil accumulation and the concentrations of the above mentioned mediators in WT mice. All these observations support our hypothesis that the ceramide-CD300f interaction suppresses innate immune responses in the CLP model.

Inoculation of an adequate number (10⁷) of either WT or CD300f ^−/− neutrophils equally improved survival of WT mice after CLP, suggesting that robust accumulation of neutrophils prevented sepsis after CLP in CD300f ^−/− mice. On the other hand, inoculation of low numbers (10⁶) of CD300f ^−/− neutrophils, but not WT neutrophils, increased the number of recipient neutrophils recruited to the peritoneal cavity, concentrations of neutrophil chemoattractants in PLF, and survival after CLP in WT mice. In addition, CD300f ^−/− Kit ^W-sh/W-sh mice were less prone to CLP-induced death than Kit ^W-sh/W-sh mice were. These results implicated CD300f ^−/− neutrophils in the resistance of CD300f ^−/− mice to septic death. We can theorize that once recruited to inflamed tissues containing extracellular ceramides, CD300f ^−/− neutrophils release more neutrophil chemoattractants than WT neutrophils do, thus accelerating neutrophil accumulation in the CLP model.

The crucial role of CD300f-deficient mast cells in CLP-operated CD300f ^−/− mice was illustrated by several lines of evidence: the concentrations of neutrophil chemoattractants and cysteinyl LTs in PLF, the number of neutrophils recruited to the peritoneal cavity, and survival after CLP were increased by implantation of CD300f ^−/− mast cells, but not WT mast cells, in two types of mast cell-deficient mice (Kit ^W-sh/W-sh or Mcpt5-Cre/R-DTA). In addition, similar results were obtained in CD300f ^−/− Kit ^W-sh/W-sh mice, confirming the non-redundant and indispensable role of CD300f ^−/− mast cells in this model. Recent studies suggested that whether mast cells have a beneficial or detrimental effect on survival during bacterial infection depends on the circumstances, including the type and severity of infection^{33, 34}. In fact, under our experimental conditions, WT mast cells appeared to not promote survival after CLP. It was evident, however, that CD300f ^−/− mast cells drive neutrophil recruitment and enhance survival after CLP; these data are suggestive of an outstanding role of CD300f ^−/− mast cells in prevention of sepsis. Prominent mucosal edema in the cecum of CLP-operated CD300f ^−/− mice can be attributed to upregulation of factors increasing vascular permeability, including cysteinyl LTs, which are released mainly by mast cells. On the other hand, the increased concentrations of mast cell-derived chemical mediators known to improve survival after CLP^{35, 36} may also contribute to the resistance of CD300f ^−/− mice to septic peritonitis.

Collectively, these results support our hypothesis that resident mast cells collaborate with the recruited neutrophils to accelerate neutrophil accumulation at sites of infection in CD300f ^−/− mice although a contributory role of other CD300f ^−/− myeloid cells cannot be ruled out. On the other hand, the ceramide-CD300f binding failed to significantly influence the in vitro bactericidal abilities of mast cells or neutrophils in response to the presence of E. coli. Hence, we can conclude that the resistance of CD300f ^−/− mice to CLP lethality is likely to the result of efficient elimination of E. coli by vast numbers of neutrophils recruited to the peritoneal cavity where large amounts of the factors inducing neutrophil recruitment were released by resident mast cells and by recruited neutrophils.

CD300f was reported to recognize PS^{21, 25}, but our results did not implicate this interaction in the CD300f-mediated inhibition of innate immune responses in our CLP model. This conclusion seems to be supported by a recent finding that apoptotic cell-mediated inhibition of cytokine and chemokine production in CLP-operated mice depends on the PS-CD300a interaction²². It was therefore possible to assume that the ceramide-CD300f interaction cooperated with the PS-CD300a interaction to inhibit innate immune responses in our CLP model. Thus, the ceramide-CD300f binding inhibits CLP-induced neutrophil accumulation to sites of infection as well as IgE-dependent allergic reactions, ATP-mediated experimental colitis, or LPS-induced skin inflammation; however, the ceramide-CD300f binding is either detrimental or beneficial to human health in the former and latter case, respectively¹³.

It is worth mentioning that even post-CLP treatment with the anti-ceramide Ab improved the survival of the septic mice. Although most of the anti-inflammatory therapies for sepsis have failed in clinical trials, novel strategies to relieve immunosuppression in sepsis are emerging². In this sense, CD300f is a promising target because blocking of CD300f function stimulates innate host responses that can overcome both primary bacterial infections and secondary cosmic infections. Because human CD300f binds both ceramide and sphingomyelin²⁰, a novel drug specifically disrupting this binding may be effective against bacterial infections. In addition, it is possible that combined targeted therapies will synergistically improve the survival rates of septic patients.

In conclusion, ceramide-CD300f interaction inhibits innate host responses in a model of septic peritonitis. Disruption of this interaction stimulates neutrophil accumulation at infection sites. Accordingly, the development of an intervention involving CD300f seems to be an appealing approach to the prophylaxis of bacterial sepsis.

Methods

Mice

C57BL/6 J (Ly5.1⁺), C57BL/6 J (Ly5.2⁺), CD300f ^−/−, Kit ^w-sh/w-sh, Kit ^w-sh/w-sh CD300f ^−/−, and Mcpt5-Cre/R-DTA mice were used in this study^{13, 31}.

Ethics statement

All animal experiments were approved by the ethical committee of the University of Tokyo (approval no 20–8) and Juntendo University (approval no 270015). All the methods were carried out in accordance with the approved guidelines and regulations.

Antibodies (Abs) and other reagents

The following Abs were used: rat anti-LMIR3/CD300f (3–14–11) was obtained from ACTGen; anti-Flag (M2) and mouse IgG1 (MOPC21) were purchased from Sigma-Aldrich; fluorescein isothiocyanate (FITC)-conjugated anti-CD11b (M1/70), Gr-1 (RB6-8C5), F4/80 (BM8), or the high-affinity IgE receptor (FcεRI)-α (MAR-1), phycoerythrin (PE)-conjugated anti-Gr-1 (RB6-8C5), CD45.1 (A20), CD45.2 (104), Ly-6G (1A8), CD11b (M1/70), or c-kit (2B8) or streptavidin- or allophycocyanin (APC)-conjugated anti-c-kit (2B8) and rat IgG2a (eBR2a) were from eBioscience; anti-ceramide Ab (MID 15B4) was from Enzo Life Sciences, mouse IgM (MOPC-104E) was from BioLegend, rat IgG1/2a (G28-5) was from BD Biosciences. Clodronate liposomes were from Sigma-Aldrich. All the cytokines were obtained from R&D Systems. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (phosphatidylcholine [PC]) and 1,2-Dipalmitoyl-sn-glycero-3-phosphoserine (phosphatidylserine [PS]) were from Echelon Biosciences Inc. All other reagents were from Sigma unless stated otherwise¹³.

Cells

BMMCs and BMMC transfectants were generated as described elsewhere^{13, 37}. Neutrophils were isolated from mouse BM by means of a three-layer gradient as described previously^{12, 38, 39}. Peritoneal macrophages and BM-derived macrophages were isolated as described elsewhere^{17, 26}.

Cell stimulation

Lipids were diluted to a concentration of 20 μg/ml in methanol. MaxiSorp 96-well plates (Nunc, catalog No. 430341) were coated with 50 μl of each solution, air-dried, and washed twice with the medium, as previously described¹³. BMMCs, neutrophils, or peritoneal macrophages were pre-incubated on a lipid-coated plate for 1 h before stimulation with 5 × 10⁷ CFU/ml heat-killed E. coli ¹³.

Peritonitis induced by CLP or by inoculation of E. coli

CLP was performed as previously described^{10, 11, 40,41,42}. Briefly, male mice were anesthetized, and the cecum was exposed through a 1.0- to 1.5-cm abdominal midline incision. The cecum was ligated at half the distance between the distal pole and the base of the cecum, followed by a single puncture with either a G-18 needle (CLP with 80–100% lethality among wild-type [WT] mice) or a G-22 needle (mild CLP with 40–60% lethality among WT mice). Sham-operated mice underwent an identical laparotomy without CLP. The operated mice received a subcutaneous injection of sterile saline (1 ml) for fluid resuscitation after the abdominal incision was closed. Survival after CLP was assessed every 12 h for 7 d. Peritoneal lavage fluid (PLF) (1 ml PBS), serum, or cecum samples were collected from the mice euthanized 2, 4, or 24 h after CLP. In some experiments, 4 μg of either the anti-ceramide Ab or isotype control Ab or 300 μg of either CD300f-Fc or control Fc was intraperitoneally injected immediately after or at the indicated time points after CLP. To induce E. coli peritonitis, E. coli was isolated from mouse feces with Drigalski agar (Nissui), was grown in Luria-Bertani broth overnight, washed with PBS four times, and re-suspended in PBS (10⁹ colony forming unit [CFU]/ml)^{1, 40, 43}. Female mice were intraperitoneally injected with a suspension of E. coli (4.0 × 10⁸ CFU per mouse as the minimum lethal dose). For some experiments, E. coli was killed by heat (95 °C for 2 min)³³.

Analysis of in vivo neutrophil migration

Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD300f ^−/− (Ly5.2⁺) neutrophils mixed with WT (Ly5.1⁺) neutrophils were intravenously injected into WT (Ly5.1⁺) mice 1 h before CLP. The peritoneal lavage cells or PB cells 4 h after CLP were stained with PE-conjugated anti-Ly5.1 (CD45.1) Ab or ant-Ly5.2 (CD45.2) Ab, and the proportions of CD300f ^−/− (Ly5.2⁺) cells among CFSE-positive neutrophils recruited to the peritoneal cavity or among CFSE-positive PB neutrophils were calculated by means of fluorescence-activated cell sorting (FACS).

Preparation of lipid-containing vesicle

After 1 mg of a dry lipid (C-24 ceramide, PC, or PS) was hydrated with 1 ml of PBS, vesicle was generated by means of Avanti Mini-Etruder (Avanti Polar Lipids, Inc.) according to the manufacturer’s instructions, as previously described^{13, 20}.

Preparation of Fc fusion proteins

These proteins were purified as described^{1, 7}. Endotoxin levels of Fc fusion proteins were less than 0.01 ng/μg protein as determined by the limulus amebocyte lysate test (Lonza)^{13, 18}.

Quantification of cytokines, chemokines, and LTs and the degranulation assay

Enzyme-linked immunosorbent assay (ELISA) kits for IL-6, TNF-α, KC, MIP-2, and LTB4 (R&D Systems) or cysteinyl LTs and LTC4 (Cayman Chemical Company) were used. The release of β-hexosaminidase was estimated as described elsewhere¹³.

Flow cytometry

Flow cytometric analysis was performed on a FACSCalibur (BD Biosciences) equipped with the CellQuest software and FlowJo software (Tree Star), as previously described¹³.

DNA constructs

pMXs-internal ribosome entry sites (IRES)-puro^r (pMXs-IP), pMXs-Flag-CD300f or CD300f-Y241F/Y289F/Y325F-IP, and the pME18S-hIgG1 Fc vector (a kind gift from H. Arase, Osaka University) were described previously^{13, 44, 45}.

Transfection and infection

Retroviral transfection was performed as described elsewhere^{13, 44, 45}. Cells were infected with retroviruses generated by transient transfection of PLAT-E packaging cells.

Reconstitution with BMMC

Mast cell reconstitution was performed as previously described¹³. In brief, Kit ^W-sh/W-sh mice or Mcpt5-Cre/R-DTA mice were injected intraperitoneally with either 5 × 10⁶ WT or CD300f ^−/− BMMCs 6 weeks before CLP. Reconstitution of mast cells was confirmed by toluidine blue staining or fluorescence-activated cell sorting (FACS).

Macrophage reconstitution

Macrophage reconstitution was performed as previously described⁴⁶. Briefly, clodronate liposomes (50 mg in 200 μl per mouse) were intraperitoneally injected into WT mice to deplete macrophages. Two days later, 10⁷ WT or CD300f ^−/− BM-derived macrophages were intraperitoneally injected into macrophage-depleted mice 6 h before CLP induction.

Transwell migration assays

These assays were performed using Transwell filters with 3-μm pores (BD Falcon), as previously described²⁶. Briefly, the upper wells contained 1.5 × 10⁶ cells in 0.2 ml of the medium and the lower wells were filled with 0.6 ml of PLF from CLP-operated mice. After incubation for 60 min, neutrophils that migrated into the lower wells were counted.

Killing assays

The indicated cells were incubated with E. coli (4 × 10⁵ cells per 10⁶ CFU of E. coli) for 60 min. Enumeration of viable E. coli cells involved colony-counting methods^{40, 42}.

Quantitation of ceramides

Concentrations of ceramides were measured as previously described³⁰. Briefly, PLF (1 ml PBS) or plasma samples were collected from WT mice before or 4 h after a sham or CLP operation. Total lipids were extracted by the method of Bligh and Dyer. The lipid extracts were dissolved in chloroform:methanol:2-propanol (10:45:45, v/v/v) so that the final concentration of the internal standard was 50 nM. This lipid solution was subjected to reversed-phase liquid chromatography with mass spectrometry (LC/MS). An Agilent 1100 Series LC/MSD SL system equipped with a multi-ion source, ChemStation software, a 1,100-well plate autosampler (Agilent Technologies), and an L-column ODS (2.1 mm i.d. ×150 mm; Chemicals Evaluation and Research Institute) was used. Chromatographic separation of the lipids was attained at a flow rate of 0.2 mL/min using a binary gradient solvent system of mobile phases. Each ceramide species was detected by selected ion monitoring as m/z [M + CH₃COO]⁻. C24-ceramide (d18:1/24:0), C18-ceramide (d18:1/18:0), C16-ceramide (d18:1/16:0) (Toronto Research Chemicals Inc.), N-Nervonoyl-D-erythro-sphingosine (d18:1/24:1) (Cayman Chemical Co.), N-Behenoyl-D-erythro-sphingosine (d18:1/22:0) (Avanti Polar Lipids), and N-Arachidoyl-D-erythro-Sphingosine (d18:1/20:0) (Avanti Polar Lipids) served as standards. N-Heptadecanoyl-D-erythro-sphingosine (d18:1/17:0) (Avanti Polar Lipids) was used as an internal control.

Statistical analyses

The results are expressed as means ± standard deviation (SD). Unpaired Student’s t test was used to analyze the differences between groups. The Kaplan-Meier method and log-rank tests were used to analyze the survival data. *p < 0.01 or **p < 0.05 was assumed to mean statistical significance.

References

Bouchon, A., Facchetti, F., Weigand, M. A. & Colonna, M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410, 1103–1107 (2001).
Article ADS CAS PubMed Google Scholar
Rittirsch, D., Flierl, M. A. & Ward, P. A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8, 776–787 (2008).
Article CAS PubMed PubMed Central Google Scholar
Peters-Golden, M., Canetti, C., Mancuso, P. & Coffey, M. J. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 174, 589–594 (2005).
Article CAS PubMed Google Scholar
Phillipson, M. & Kubes, P. The neutrophil in vascular inflammation. Nat Med 17, 1381–1390 (2011).
Article CAS PubMed Google Scholar
De Filippo, K. et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 121, 4930–4937 (2013).
Article PubMed Google Scholar
St John, A. L. & Abraham, S. N. Innate immunity and its regulation by mast cells. J Immunol 190, 4458–4463 (2013).
Article Google Scholar
Colonna, M. TREMs in the immune system and beyond. Nat Rev Immunol 3, 445–453 (2013).
Article Google Scholar
Kondo, T., Kawai, T. & Akira, S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol 33, 449–458 (2012).
Article CAS PubMed Google Scholar
Buras, J. A., Holzmann, B. & Sitkovsky, M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4, 854–865 (2005).
Article CAS PubMed Google Scholar
Rittirsch, D., Huber-Lang, M. S., Flierl, M. A. & Ward, P. A. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4, 31–36 (2009).
Article CAS PubMed PubMed Central Google Scholar
Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 19, 198–208 (2011).
Article CAS PubMed Google Scholar
Izawa, K. et al. Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3. J Biol Chem 282, 17997–18008 (2007).
Article CAS PubMed Google Scholar
Izawa, K. et al. The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide. Immunity 37, 827–839 (2012).
Article CAS PubMed Google Scholar
Chung, D. H. et al. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol 171, 6541–6548 (2003).
Article CAS PubMed Google Scholar
Xi, H. et al. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med 207, 7–16 (2010).
Article CAS PubMed PubMed Central Google Scholar
Kumagai, H. et al. Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow derived mast cells. Bioche. Biophys Res Commun 307, 719–729 (2003).
Article CAS Google Scholar
Yamanishi, Y. et al. Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells. Blood 111, 688–698 (2008).
Article CAS PubMed Google Scholar
Yotsumoto, K. et al. Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med 198, 223–233 (2003).
Article CAS PubMed PubMed Central Google Scholar
Cannon, J. P., O’Driscoll, M. & Litman, G. W. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics 64, 39–47 (2011).
Article PubMed Google Scholar
Izawa, K. et al. Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation. J Allergy Clin Immunol 133, 270–273 (2014).
Article CAS PubMed Google Scholar
Choi, S. C. et al. Cutting edge: mouse CD300f (CMRF-35-like molecule-1) recognizes outer membrane-exposed phosphatidylserine and can promote phagocytosis. J Immunol 187, 3483–3487 (2011).
Article CAS PubMed PubMed Central Google Scholar
Nakahashi-Oda, C. et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. J Exp Med 209, 1493–1503 (2012).
Article CAS PubMed PubMed Central Google Scholar
Simhadri, V. R. et al. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119, 2799–2809 (2012).
Article CAS PubMed PubMed Central Google Scholar
Takahashi, M. et al. Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition. J Biol Chem 288, 7662–7675 (2013).
Article CAS PubMed PubMed Central Google Scholar
Tian, L. et al. p85α recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression. Nat Commun 5, 3146 (2014).
PubMed PubMed Central Google Scholar
Yamanishi, Y. et al. TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J Exp Med 207, 1501–1511 (2010).
Article CAS PubMed PubMed Central Google Scholar
Zheng, W. et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 1758, 1864–1884 (2006).
Article CAS PubMed Google Scholar
Matsukawa, T. et al. Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation. Gut 65, 777–787 (2016).
Article CAS PubMed Google Scholar
Shiba, E. et al. Ceramide-CD300f binding inhibits lipopolysaccharide-induced skin inflammation. J Biol Chem 292, 2924–2932 (2017).
Article PubMed PubMed Central Google Scholar
Ohno, Y. et al. Essential role of the cytochrome P450 CYP4F22 in the production of acylceramide, the key lipid for skin permeability barrier formation. Proc Natl Acad Sci U S A 112, 7707–7712 (2015).
Article ADS CAS PubMed PubMed Central Google Scholar
Dudeck, A. et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34, 973–984 (2011).
Article CAS PubMed Google Scholar
Drobnik, W. et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in septic patients. J Lipid Res 44, 754–761 (2003).
Article CAS PubMed Google Scholar
Grimbaldeston, M. A. et al. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167, 835–848 (2005).
Article CAS PubMed PubMed Central Google Scholar
Piliponsky, A. M. et al. Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am J Pathol 176, 926–938 (2010).
Article CAS PubMed PubMed Central Google Scholar
Maurer, M. et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432, 512–516 (2004).
Article ADS CAS PubMed Google Scholar
Piliponsky, A. M. et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis in a mouse model of sepsis. Nat Med 14, 392–398 (2008).
Article CAS PubMed PubMed Central Google Scholar
Kitaura, J. et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Pro Natl Acad Sci USA 100, 12911–12916 (2003).
Article ADS CAS Google Scholar
Mócsai, A., Zhou, M., Meng, F., Tybulewicz, V. L. & Lowell, C. A. Syk is required for integrin signaling in neutrophils. Immunity 16, 547–558 (2002).
Article PubMed Google Scholar
Mócsai, A., Ligeti, E., Lowell, C. A. & Berton, G. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 162, 1120–1126 (1999).
PubMed Google Scholar
Pinheiro, daS. et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med 13, 1368–1374 (2007).
Article Google Scholar
Walley, K. R., Lukacs, N. W., Standiford, T. J., Strieter, R. M. & Kunkel, S. L. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64, 4733–4778 (1996).
CAS PubMed PubMed Central Google Scholar
Moreno, S. E. et al. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J Immunol 177, 3218–3224 (2006).
Article CAS PubMed Google Scholar
Tomita, T., Blumenstock, E. & Kanegasaki, S. Phagocytic and chemiluminescent responses of mouse peritoneal macrophages to living and killed Salmonella typhimurium and other bacteria. Infect Immun 323, 1242–1248 (1981).
Google Scholar
Kitamura, T. et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 31, 1007–1014 (2003).
Article CAS PubMed Google Scholar
Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7, 1063–1066 (2000).
Article CAS PubMed Google Scholar
Han, C., Jin, J., Xu, S., Li, N. & Cao, X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 8, 734–742 (2010).
Article Google Scholar

Download references

Acknowledgements

We thank Hisashi Arase (Osaka University) for providing the plasmids. This study was supported by grants from the Ministry of Education, Science, Technology, Sports and Culture, Japan (JSPS KAKENHI Grant Number 23390257 and 26293231).

Author information

Authors and Affiliations

Atopy Research Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113–8421, Japan
Kumi Izawa, Akie Maehara, Masamichi Isobe, Ayako Kaitani, Emiko Shiba, Ayako Takamori, Shino Uchida, Koichiro Uchida, Keiko Maeda, Nobuhiro Nakano, Toshiaki Shimizu, Hideoki Ogawa, Ko Okumura & Jiro Kitaura
Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
Kumi Izawa, Akie Maehara, Masamichi Isobe, Toshihiro Matsukawa, Mariko Takahashi, Ayako Kaitani, Yoshinori Yamanishi, Toshihiko Oki, Toshio Kitamura & Jiro Kitaura
Analytical Science Laboratories, Kao Corporation, Haga, Tochigi, 321-3497, Japan
Yuka Yasuda & Junko Ishikawa
Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan
Makoto Urai, Yasutaka Hoshino, Keigo Ueno & Yuki Kinjo
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 060-0808, Japan
Toshihiro Matsukawa
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan
Emiko Shiba & Toshiaki Shimizu
Departments of Gastroenterology Immunology, Juntendo University Graduate School of Medicine, Tokyo, Japan
Shino Uchida
Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan
Yoshinori Yamanishi
Department of Infection Biology, University Hospital Erlangen and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
David Voehringer
Medical Faculty “Carl-Gustav Carus”, Institute for Immunology, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany
Axel Roers
Laboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan
Susumu Nakae

Authors

Kumi Izawa
View author publications
You can also search for this author in PubMed Google Scholar
Akie Maehara
View author publications
You can also search for this author in PubMed Google Scholar
Masamichi Isobe
View author publications
You can also search for this author in PubMed Google Scholar
Yuka Yasuda
View author publications
You can also search for this author in PubMed Google Scholar
Makoto Urai
View author publications
You can also search for this author in PubMed Google Scholar
Yasutaka Hoshino
View author publications
You can also search for this author in PubMed Google Scholar
Keigo Ueno
View author publications
You can also search for this author in PubMed Google Scholar
Toshihiro Matsukawa
View author publications
You can also search for this author in PubMed Google Scholar
Mariko Takahashi
View author publications
You can also search for this author in PubMed Google Scholar
Ayako Kaitani
View author publications
You can also search for this author in PubMed Google Scholar
Emiko Shiba
View author publications
You can also search for this author in PubMed Google Scholar
Ayako Takamori
View author publications
You can also search for this author in PubMed Google Scholar
Shino Uchida
View author publications
You can also search for this author in PubMed Google Scholar
Koichiro Uchida
View author publications
You can also search for this author in PubMed Google Scholar
Keiko Maeda
View author publications
You can also search for this author in PubMed Google Scholar
Nobuhiro Nakano
View author publications
You can also search for this author in PubMed Google Scholar
Yoshinori Yamanishi
View author publications
You can also search for this author in PubMed Google Scholar
Toshihiko Oki
View author publications
You can also search for this author in PubMed Google Scholar
David Voehringer
View author publications
You can also search for this author in PubMed Google Scholar
Axel Roers
View author publications
You can also search for this author in PubMed Google Scholar
Susumu Nakae
View author publications
You can also search for this author in PubMed Google Scholar
Junko Ishikawa
View author publications
You can also search for this author in PubMed Google Scholar
Yuki Kinjo
View author publications
You can also search for this author in PubMed Google Scholar
Toshiaki Shimizu
View author publications
You can also search for this author in PubMed Google Scholar
Hideoki Ogawa
View author publications
You can also search for this author in PubMed Google Scholar
Ko Okumura
View author publications
You can also search for this author in PubMed Google Scholar
Toshio Kitamura
View author publications
You can also search for this author in PubMed Google Scholar
Jiro Kitaura
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

K.I. performed all the experiments and participated in writing the manuscript. A.M., M. I., Y.Y., M.U., Y.H., K.U., T.M., M.T., A.K., E.S., A.T., S.U., K.U., K.M., N.N., Y.Y., T.O., and J.I. assisted with the experiments. D.V., A.R., and S.N. provided mice. Y.K., T.S., H.O., and K.O. analyzed the data. T.K. and J.K. conceived the project, analyzed the data, and actively participated in manuscript writing.

Corresponding authors

Correspondence to Toshio Kitamura or Jiro Kitaura.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Supplemntal figures and figure legends

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Izawa, K., Maehara, A., Isobe, M. et al. Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment. Sci Rep 7, 4298 (2017). https://doi.org/10.1038/s41598-017-04647-z

Download citation

Received: 16 February 2017
Accepted: 17 May 2017
Published: 27 June 2017
DOI: https://doi.org/10.1038/s41598-017-04647-z

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.